Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-07-30

FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)

View source ↗

Summary

The FDA has approved a supplemental application for Remodulin (treprostinil) filed by United Therapeutics Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Remodulin (treprostinil)

Snippet

SUPPL AP for REMODULIN (TREPROSTINIL)